Title
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant
Phase
Phase 3Lead Sponsor
University of WashingtonStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
VZV Infection After Bone Marrow TransplantationIntervention/Treatment
aciclovir ...Study Participants
120The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT) recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective prevention strategy has not been established.
77 marrow allograft recipients at risk for VZV reactivation were randomized to oral acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed for toxicity and clinical evidence of herpes zoster infection.
Inclusion Criteria: 10 years or older Both sex (male or female) Allogeneic transplant patient for hematologic malignancy or aplastic anemia Exclusion Criteria: Previous intolerance to acyclovir Patients who are unavailable for follow-up Patients in whom drug compliance may be a problem Evidence of active VZV infection VZV infection in the initial 1 month after transplant Pregnant women, lactating women, or those not using adequate contraception Creatinine > 3.0 mg/dl.
